Dr. Adi Zuloff-Shani reports

CLEARMIND MEDICINE ANNOUNCES RECEIPT OF NASDAQ DELISTING NOTICE AND PLAN FOR IMMEDIATE RECOMPLIANCE

Clearmind Medicine Inc. has received a staff delisting determination from the listing qualifications department of the Nasdaq Stock Market LLC. The company was notified that Nasdaq has determined to delist the company's securities from the Nasdaq Capital Market for failure to maintain a minimum bid price of $1 per share for 30 consecutive business days in accordance with Nasdaq Listing Rule 5550(a)(2).

The company plans to appeal the staff's determination to a hearings panel. A hearing request will stay the suspension of the company's securities and the filing of the Form 25-NSE pending the panel's decision.

As part of the plan to regain compliance with the minimum bid price rule, the company intends to conduct a reverse stock split as soon as reasonably practicable, subject to applicable law and Nasdaq rules. On Nov. 14, the company's shareholders approved a reverse stock split, which the company expects will be made effective imminently. Additional details regarding the reverse stock split will be announced in the coming days.

"The company's shareholders have already approved a reverse stock split, which is expected within the next few weeks, as part of our plan to regain compliance with the minimum bid price rule," said Clearmind's chief executive officer, Dr. Adi Zuloff-Shani. "We are looking forward to updating our shareholders regarding the company's compliance with the minimum bid price rule soon."

About Clearmind Medicine Inc.

Clearmind is a psychedelic pharmaceutical biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and underserved health problems, including alcohol use disorder. Its primary objective is to research and develop psychedelic-based compounds and attempt to commercialize them as regulated medicines, foods or supplements.

The company's intellectual portfolio currently consists of 14 patent families. The company intends to seek additional patents for its compounds whenever warranted and will remain opportunistic regarding the acquisition of additional intellectual property to build its portfolio.

We seek Safe Harbor.